Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Taste Alteration, CTCAE"
Page 1
Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study.
Malta CEN, de Lima Martins JO, Carlos ACAM, Freitas MO, Magalhães IA, de Vasconcelos HCA, de Lima Silva-Fernandes IJ, de Barros Silva PG. Malta CEN, et al. Support Care Cancer. 2022 Jan;30(1):313-325. doi: 10.1007/s00520-021-06219-4. Epub 2021 Jul 20. Support Care Cancer. 2022. PMID: 34283319
PURPOSE: This study retrospectively analyzed the risk factors for transchemotherapy dysgeusia. METHODS: Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of dysgeusia based on the Common Terminology Criteria for Adverse Even …
PURPOSE: This study retrospectively analyzed the risk factors for transchemotherapy dysgeusia. METHODS: Before each chemotherapy cycl …
Taste disorders following cancer treatment: report of a case series.
Epstein JB, de Andrade E Silva SM, Epstein GL, Leal JHS, Barasch A, Smutzer G. Epstein JB, et al. Support Care Cancer. 2019 Dec;27(12):4587-4595. doi: 10.1007/s00520-019-04758-5. Epub 2019 Mar 29. Support Care Cancer. 2019. PMID: 30927113
RESULTS: According to STTA, hematology cases reported the incidence of grades 2 and 3 taste disturbances as 60% and 40%, respectively. For HNC patients, the incidence of grades 2 and 3 was 44% each. ...In the hematologic and HNC patient groups, …
RESULTS: According to STTA, hematology cases reported the incidence of grades 2 and 3 taste disturbances as 60% and 40% …
Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.
Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM. Moroney LB, et al. Support Care Cancer. 2019 Feb;27(2):573-581. doi: 10.1007/s00520-018-4352-5. Epub 2018 Jul 17. Support Care Cancer. 2019. PMID: 30019149
Dysphagia and acute toxicity data was collected weekly during treatment and at 2, 4 and 12 weeks post-treatment using the Functional Oral Intake Scale, diet descriptors and CTCAE v4.0. RESULTS: In both groups, minimal treatment toxicities (grades 0-1) were ob …
Dysphagia and acute toxicity data was collected weekly during treatment and at 2, 4 and 12 weeks post-treatment using the Functional …
Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.
Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM. Moroney LB, et al. Head Neck. 2018 Sep;40(9):1955-1966. doi: 10.1002/hed.25182. Epub 2018 May 13. Head Neck. 2018. PMID: 29756244
Dysphagia and acute toxicity data were collected weekly during treatment and at 2, 4, and 12 weeks posttreatment using the Functional Oral Intake Scale, diet descriptors, and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. RESULTS: Patients exper …
Dysphagia and acute toxicity data were collected weekly during treatment and at 2, 4, and 12 weeks posttreatment using the Functional …
Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study.
Chihiro S, Hirai T, Kaneda M, Okamoto A, Kato H, Tanaka K, Kondo E, Ikeda T, Iwamoto T. Chihiro S, et al. Medicine (Baltimore). 2023 Jul 28;102(30):e34123. doi: 10.1097/MD.0000000000034123. Medicine (Baltimore). 2023. PMID: 37505180 Free PMC article.
The incidence of grade 2 dysgeusia was significantly higher in patients with grade 3 anemia (P = .034). ...A high cumulative dose of previously administered carboplatin and dysgeusia may be associated with olaparib-induced anemia....
The incidence of grade 2 dysgeusia was significantly higher in patients with grade 3 anemia (P = .034). ...A hig …
Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy.
Zarinshenas R, Campbell P, Sun K, Molitoris JK, Patel AN, Witek ME, Cullen KJ, Mehra R, Hatten KM, Moyer KF, Taylor RJ, Vakharia KT, Wolf JS, Ferris MJ. Zarinshenas R, et al. Radiother Oncol. 2024 Apr;193:110112. doi: 10.1016/j.radonc.2024.110112. Epub 2024 Feb 1. Radiother Oncol. 2024. PMID: 38309587
Positive margins/extranodal extension were present in 34 cases; gross disease in 17. RT types: 39 (58.2 %) VMAT and 28 (41.8 %) PBT. Concurrent systemic therapy was delivered in 10 (14.9 %) patients. ...Median weight change was -3.8 kg (-14.1 - 5.1) for VMAT and -3 kg (-16 …
Positive margins/extranodal extension were present in 34 cases; gross disease in 17. RT types: 39 (58.2 %) VMAT and 28 (41.8 %) PBT. …